Choose a different country or region to see content for your location and shop online.
United States
Preisverleihung Feiern
Press
15.09.2020

spermidineLIFE® won the Pharma Oscar 2020!

The champagne corks are popping! On September 15th, spermidineLIFE® was elected “Most Innovative Product” at the “Pharma Trend – Image & Innovation Award 2020“. Thus, spermidineLIFE® follows up on the success of the previous year. In 2019 it was ranked 2nd place in the category “Product Innovations” by Insight Health.

On September 15th, spermidineLIFE® won the first place in the category “Most Innovative Product”, which is also known as the “Pharma Oscar”. The winner of this award is elected by numerous customers, pharmacists and doctors, who consider a number of criteria – mostly regarding product innovation, efficacy, sustainability and tolerability. Although we are proud about the recognition and acknowledgment, we primarily are thankful for all the support we got from our customers and furthermore from all our team members, which are constantly striving for more.

Since 2000, the “Pharma Award”, also known as “Pharma Oscars”, “The Golden Tablet” or “Most Innovative Product”, has been awarded to companies for creating the most innovative products. The election is based on the “Pharma Trend Survey”, which is divided into several categories. Doctors, physicians, pharmacists and patients take part in an online survey and evaluate the nominated products regarding sustainability and innovation. For further information, please visit: https://pharma-trend.com/pharma-award/#IP .

We feel honored to have been given this award, especially considering that we are still a rather small start-up company and were competing with 59 other outstanding pharmaceutical product developments from strong global players, such as Bayer, Sonofi and Novartis. Furthermore, the fact that this award is based on the product’s efficacy and tolerability instead of some superficial criteria, reflects the innovative character of our company and motivates us to continue our efforts. At this point we also want to say thank you to our top-class scientific advisory board, which has accompanied us on our journey for years now and continues to push us forward.

Already within our first year as Longevity Labs+ we were able to celebrate a great success: in 2019 spermidineLIFE® was awarded second place in terms of sales for product launches in Austrian pharmacies by “Insight Health”. Receiving the Pharma Oscar in the following year shows us, that we are on the right path and that we are making a difference. More and more people recognize the relevance of cellular health and how it is connected to our overall well-being. This is one of our main goals: To give cells the spotlight they truly deserve!

Of course, we do not rest on our laurels. The next chapter of our company history is just beginning.  On the 1st of October we are going to launch our next innovation: spermidineLIFE® Immune. When creating this new product, we again focused on our cells – but this time, we dedicated it to our immune cells. Especially during the cold seasons of the year, our immune system has to fight many battles and plays an important role regarding our overall health status. To maintain a smoothly functioning immune system, we should take care of our immune cells and supply them in the best possible way we can.

Related Posts

Preisverleihung Feiern
Press
15.09.2020
spermidineLIFE® won the Pharma Oscar 2020!
The champagne corks are popping! On September 15th, spermidineLIFE® was elected “Most Innovative Product” at the “Pharma Trend – Image & Innovation Award 2020“. Thus, spermidineLIFE® follows up on the success of the previous year. In 2019 it was ranked 2nd place in the category “Product Innovations” by Insight Health.
Longevity Labs Team
Press
15.05.2019
Hannes Androsch invests in Longevity Labs
With spermidineLIFE®, a Longevity Labs innovation, a high-dose product containing spermidine premieres for the first time on the global market. Former Austrian Finance Minister Dr. Hannes Androsch has been found as an investor.